ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
FARSHAD NOSRATIAN MD

Cardiovascular Disease

6,759

$302K

392
309 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

16%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$45
Average prescription price

Avg: $67

DAVID ROBERTS M.D

Cardiovascular Disease

650

$57K

117
109 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

18%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$88
Average prescription price

Avg: $67

RASHID MASSUMI MD FACC

Cardiovascular Disease

4,262

$231K

189
182 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

8%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$54
Average prescription price

Avg: $67

KAMLESH DHAWAN MD

Cardiovascular Disease

4,190

$170K

196
170 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

12%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$41
Average prescription price

Avg: $67

KRISHAN KRISHNA MD

Cardiovascular Disease

4,285

$166K

201
70 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$39
Average prescription price

Avg: $67

WILLIAM DISCEPOLO M.D.

Cardiovascular Disease

369

$13.6K

87
74 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

16%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$37
Average prescription price

Avg: $67

YING-SUEN KONG MD

Cardiovascular Disease

1,595

$108K

87
86 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$67
Average prescription price

Avg: $67

NGAI NGUYEN MD

Cardiovascular Disease

25,657

$3.37M

1277
1207 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

49%
prescriptions for brand name drugs

Avg: 28%

$131
Average prescription price

Avg: $67

ROBERT KARNS M.D.

Cardiovascular Disease

2,082

$168K

218
174 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 28%

$80
Average prescription price

Avg: $67

PRAKASH PATEL MD

Cardiovascular Disease

6,361

$284K

367
311 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

10%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$45
Average prescription price

Avg: $67

JUAN ALMAGUER MD

Cardiovascular Disease

19,375

$1.11M

673
600 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$57
Average prescription price

Avg: $67

BERNARD COOKE M.D.

Cardiovascular Disease

3,363

$138K

147
131 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 28%

$41
Average prescription price

Avg: $67

JOHN YU MD

Cardiovascular Disease

4,902

$262K

234
188 are 65+

8%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$53
Average prescription price

Avg: $67

ROMESH JAPRA M.D.

Cardiovascular Disease

10,228

$632K

622
505 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$62
Average prescription price

Avg: $67

YUZEF GUROVICH M.D., PH.D., FACIP

Cardiovascular Disease

5,403

$427K

148
115 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 28%

$79
Average prescription price

Avg: $67

CHEUNG LEUNG M. D.

Cardiovascular Disease

14,796

$1.11M

574
502 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$75
Average prescription price

Avg: $67

MINH NGUYEN MD

Cardiovascular Disease

20,502

$1.26M

706
598 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

IQBAL OMARALI M.D.

Cardiovascular Disease

3,054

$184K

235
214 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$60
Average prescription price

Avg: $67

MEHDI ZARGARIAN M.D.

Cardiovascular Disease

2,918

$87.7K

234
189 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 28%

$30
Average prescription price

Avg: $67

TOM YEH M.D.

Cardiovascular Disease

28,209

$1.52M

772
749 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$54
Average prescription price

Avg: $67

ROBERT STEIN M.D.

Cardiovascular Disease

6,600

$260K

423
395 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 28%

$39
Average prescription price

Avg: $67

JOHN MOREY M.D.

Cardiovascular Disease

10,967

$482K

503
482 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

13%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 28%

$44
Average prescription price

Avg: $67

WILLIAM MANN MD

Cardiovascular Disease

2,116

$268K

116
98 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 28%

$127
Average prescription price

Avg: $67

MOHD. QAISAR KHAN MD

Cardiovascular Disease

5,738

$244K

192
173 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

MICHAEL CAO MD

Cardiovascular Disease

1,424

$60.5K

111
90 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 28%

$42
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank